Bristol-Myers Squibb

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Aktis Oncology is a biotechnology company developing targeted radiopharmaceuticals for treating various solid tumor cancers. Its proprietary platforms generate tumor-targeting agents with optimal properties for alpha radiotherapy, ensuring high tumor penetration and long residence time to maximize tumor elimination while minimizing side effects.

Abata Therapeutics is a biotechnology company dedicated to developing innovative cell therapies for patients suffering from progressive multiple sclerosis and other severe autoimmune and inflammatory diseases. The company specializes in the manipulation of regulatory T cells (Tregs) to address these conditions, aiming to restore balance within the immune system. By engineering Tregs to precisely target disease-related antigens, Abata Therapeutics creates therapies that can effectively treat diseases such as multiple sclerosis and type 1 diabetes without imposing systemic immune suppression. Founded by experts in immunology and cell therapy, Abata is committed to translating advanced scientific research into meaningful therapies that improve the lives of individuals facing chronic autoimmune challenges.

Roswell Park Cancer Institute (RPCI), established in 1898 by Dr. Roswell Park, is recognized as America's first cancer center. It pioneered a multidisciplinary approach to cancer treatment, emphasizing collaboration between scientists and clinicians, which has become the benchmark for modern comprehensive cancer centers. RPCI is one of the few facilities in upstate New York designated as a "comprehensive cancer center" by the National Cancer Institute and is a member of the National Comprehensive Cancer Network (NCCN). Faculty at RPCI are actively involved in developing Clinical Practice Guidelines in Oncology™, which are the internationally recognized standards for oncology clinical policy and are continually updated to reflect the latest advancements in cancer treatment.

Envisagenics is a Huntington, New York-based company that develops a predictive analytics and bioinformatics platform to accelerate RNA therapeutics discovery. The cloud-based SpliceCore platform analyzes RNA sequencing data with artificial intelligence to identify splicing errors linked to disease, predict drug targets, and guide the design of RNA-based therapies. By translating transcriptomic insights into actionable targets, Envisagenics aims to reduce the time, cost, and risk of pharmaceutical development and to support partnerships with biopharma organizations. The firm focuses on uncovering RNA splicing alterations and translating them into therapeutic candidates, enabling researchers to validate targets and biomarkers more efficiently. The company originated as a spinout from Cold Spring Harbor Laboratory and emphasizes the use of AI and machine learning to simplify complex biomedical data for therapeutic discovery.

Asher Biotherapeutics, Inc. is a biotechnology company based in South San Francisco, California, founded in 2019. The company specializes in the development of immunotherapy drugs aimed at effectively treating cancer. Its innovative therapies are designed to enhance the immune system's ability to target and eliminate cancer cells while minimizing side effects. This focus allows healthcare providers to deliver effective treatments to patients in a shorter timeframe, aiming to improve overall outcomes in cancer care.

Q32 Bio is a clinical-stage biotechnology company focused on restoring healthy immune balance in autoimmune and inflammatory diseases by developing antibody-based therapies that modulate regulators of the innate and adaptive immune systems. Its development program includes ADX-914, a human anti-IL-7R antibody aimed at rebalancing adaptive immune function, and ADX-097, which demonstrates tissue-targeted distribution and durable pharmacokinetics/pharmacodynamics. Founded in 2017 and based in Cambridge, Massachusetts, the company emphasizes a team of scientists and immunology experts pursuing novel biologics to address diseases with limited or inadequate treatment options.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Cour Pharmaceuticals Development Co Inc, founded in 2012 and based in Elmhurst, Illinois, operates in the pharmaceutical sector with a focus on developing an immune-modifying platform. This platform aims to achieve antigen-specific tolerance for immune-mediated diseases and provides non-biological therapeutics for conditions such as acute inflammation, autoimmunity, and allergies. The company is engaged in the pharmaceutical development of products related to immunology, pathology, and cardiovascular health, enabling the treatment of various conditions, including encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Mirati Therapeutics is a clinical-stage biotechnology company focused on developing cancer therapies. It concentrates on oncology, pursuing product candidates that address the genetic and immunological drivers of cancer. The company’s pipeline includes MRTX849, a KRAS G12C inhibitor in early-stage trials for non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other tumors, and sitravatinib, a spectrum-selective kinase inhibitor in Phase II for non-small cell lung cancer, along with a KRAS G12D inhibitor program in preclinical development. Mirati collaborates with BeiGene to develop and commercialize sitravatinib and maintains a clinical collaboration with Novartis. Founded in 1995 and headquartered in San Diego, Mirati aims to translate insights into therapies that address high unmet medical needs in oncology.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.

TORL BioTherapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, antibody-based therapies aimed at enhancing the lives of cancer patients. The company specializes in antibody-drug conjugates and other biologics, focusing on oncologic diseases with significant unmet medical needs. TORL BioTherapeutics employs a strategy that involves target identification and early discovery work, allowing them to selectively advance drug programs through novel licensing agreements. This approach enables their researchers to develop proprietary drugs with unique and optimized profiles, contributing to the advancement of cancer treatment options.

Penn Medicine Princeton Cancer Center provides access to the specialist clinical services, rehabilitative care, and support required during cancer treatment and recovery from cancer.

iVexSol specializes in developing and manufacturing lentiviral vectors (LVVs), which serve as critical gene delivery vehicles for cell and gene therapies. Founded in 2018, the company is headquartered in Worcester, Massachusetts. iVexSol's innovative technology addresses the shortage of LVVs by producing them in greater quantities and at a lower cost than traditional methods. This enables shorter clinical development timelines, increased access to life-saving treatments for patients worldwide.

Cajal Neuroscience is a biotechnology company dedicated to discovering novel targets and therapeutics for neurodegeneration. It integrates human genetics, functional genomics, and advanced microscopy to accelerate drug discovery in this field.

Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer patients. Its pipeline comprises small molecule drug candidates targeting specific cancer signaling pathways, with a focus on solid tumors and hematologic malignancies.

SyntheX specializes in drug discovery using synthetic biology platforms. It identifies protein interaction modulators and enables functional protein degradation, focusing on unique mechanisms for cancer and rare disease treatments.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Turning Point Therapeutics is a clinical-stage biopharmaceutical company focused on designing and developing novel small molecule targeted oncology therapies. Its pipeline includes repotrectinib, TPX-0046, TPX-0022, and preclinical ALK inhibitor TPX-0131, targeting genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Sapience Therapeutics, Inc. is a biotechnology company focused on discovering and developing peptide-based therapeutics aimed at addressing high mortality cancers. Founded in 2015 and headquartered in Harrison, New York, the company is advancing novel therapies to meet significant unmet medical needs. Its lead product, ST101, is an inhibitor of the transcription factor C/EBPß, which is overexpressed in various cancers and plays a critical role in cellular differentiation, tumor survival, and proliferation. ST101 reduces the expression of several target genes and proteins associated with cancer cell survival and growth, inducing selective cytotoxicity in tumor types such as breast cancer, melanoma, prostate cancer, glioblastoma multiforme, lung cancer, and acute myeloid leukemia. The company aims to develop first-in-class treatments for deadly conditions, with a particular focus on glioblastoma, the most aggressive form of brain cancer.

Nuvig Therapeutics focuses on developing innovative therapies aimed at restoring immune homeostasis and rebalancing immune function. The company is dedicated to creating a pipeline of novel immune therapeutics specifically targeting chronic inflammatory and autoimmune diseases. By harnessing natural mechanisms to modulate immune responses, Nuvig seeks to enhance treatment options for patients, ultimately improving their health outcomes.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Century Therapeutics is a biotechnology company developing allogeneic cell therapies derived from induced pluripotent stem cells to treat cancer and related diseases. Its platform enables engineering of iPSCs into NK and T cells with master cell banks of modified cells that can be expanded and differentiated into standardized, off-the-shelf therapies. The company combines CRISPR-mediated gene editing, proprietary chimeric antigen receptors, Allo-Evasion technology, and manufacturing capabilities to enable scalable production of homogeneous cell products for hematologic and solid tumors. While focused on oncology, its platform also targets autoimmune and inflammatory diseases with the goal of improving cell therapy performance and reducing host immune rejection.

Compugen is a clinical-stage therapeutic discovery and development company based in Israel. It utilizes predictive computational capabilities to identify novel drug targets and biological pathways, focusing on cancer immunotherapy. Its immuno-oncology pipeline includes four clinical-stage programs targeting immune checkpoints.

Founded in 2020, Clade Therapeutics is a biopharmaceutical company headquartered in Cambridge, Massachusetts. It specializes in developing scalable, off-the-shelf stem-cell-based therapies to treat cancer, autoimmune diseases, and other life-threatening conditions.

Nitrase Therapeutics is a biopharmaceutical company developing therapies against a novel class of enzymes called nitrases, initially focusing on Parkinson’s disease. Its proprietary platform enables the identification and targeting of these enzymes to potentially slow or halt disease progression.

TreeFrog Therapeutics is a stem cell company focused on scalable production of stem cells for cell therapies. It develops and uses a proprietary end-to-end 3D bioreactor-based platform called C-Stem to enable scalable, cGMP-compliant manufacturing. Founded in 2018 and based in Pessac, France, the company aims to secure cell production and quality, accelerate clinical development, and improve market access by reducing treatment costs. The platform addresses manufacturing bottlenecks in the cell therapy sector, offering an integrated solution from cell culture to manufacturing readiness to support safe, affordable stem cell therapies.

IMIDomics is a specialized company focused on addressing Immune-Mediated Inflammatory Diseases (IMIDs). It operates by leveraging the world's largest biobank dedicated to IMIDs, alongside its extensive clinical expertise and advanced genomic analysis capabilities. The company develops an analytical platform that provides healthcare professionals with accessible insights from vast amounts of molecular and clinical data, facilitating optimized treatment strategies for patients with IMIDs. With locations at Vall d'Hebron Hospital in Barcelona, Spain, and the HudsonAlpha Institute in Huntsville, Alabama, IMIDomics aims to advance the understanding and management of these complex diseases through innovative biomarker discovery and application.

Allyx Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2018 and based in Durham, Connecticut. The company specializes in developing disease-modifying treatments for Alzheimer's Disease, with a focus on reversing neurodegeneration. Its lead product is an orally bioavailable small molecule that functions as a silent allosteric modulator of mGluR5. This innovative approach aims to provide clinicians with a therapeutic option capable of preserving cognition in patients while addressing the underlying disease mechanisms.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Aktis Oncology is a biotechnology company developing targeted radiopharmaceuticals for treating various solid tumor cancers. Its proprietary platforms generate tumor-targeting agents with optimal properties for alpha radiotherapy, ensuring high tumor penetration and long residence time to maximize tumor elimination while minimizing side effects.

Presage Biosciences, Inc. is an oncology company based in Seattle, Washington, that focuses on enhancing drug development and clinical trials through innovative technology. Founded in 2008, the company has developed the CIVO arrayed microinjection platform, which allows for the simultaneous assessment of multiple drugs or drug combinations directly within a patient's tumor. This method provides insights into drug efficacy, resistance, and potential synergies in the tumor's native microenvironment, thereby overcoming limitations associated with systemic drug administration. By using this clinical surrogate approach, Presage enables drug developers to identify ineffective compounds early in the process, ultimately streamlining the development of effective cancer treatments. The technology also facilitates the identification of drug targets and effective combinations, allowing for more accurate measurement of therapeutic responses.

Ikena Oncology, Inc. is a biotechnology company focused on discovering and developing biomarker-driven therapies for cancer treatment. It specializes in precision oncology by targeting pathways essential for cancer growth and therapeutic resistance, particularly within the Hippo and RAS signaling networks. The company's portfolio includes several preclinical and discovery-stage programs, such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-412, a kynurenine-degrading enzyme. Additionally, Ikena is developing IK-930, an oral small-molecule inhibitor of the TEAD transcription factor involved in the Hippo pathway. Ikena Oncology, originally founded as Kyn Therapeutics in 2016, rebranded in December 2019 and is headquartered in Boston, Massachusetts. The company aims to address significant medical needs in oncology through innovative drug development.

MyoKardia, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, California, specializing in the discovery, development, and commercialization of targeted therapies for rare cardiovascular diseases. Founded in 2012, the company focuses on heritable cardiomyopathies and genetically-driven heart failure stemming from biomechanical defects in cardiac muscle contraction. Its lead product candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin currently undergoing Phase III clinical trials for hypertrophic cardiomyopathy (HCM). Additionally, MyoKardia is developing Danicamtiv, which has completed Phase I and IIa trials for dilated cardiomyopathy, alongside several preclinical programs targeting related cardiovascular conditions. As of November 2020, MyoKardia operates as a subsidiary of Bristol-Myers Squibb Company.

Forbius, also known as Formation Biologics, is a clinical-stage biopharmaceutical company focused on designing and developing innovative therapeutics for cancer and fibrotic diseases. Founded in 2011 as a management-led spin-out from YM BioSciences, the company specializes in creating agents that target critical biological pathways, specifically the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways. By leveraging advanced protein engineering technologies and a deep understanding of biology, Forbius aims to produce highly effective inhibitors with unique mechanisms of action, ultimately striving to improve patient outcomes and transform lives.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, specializing in the development of tissue-targeted therapeutics aimed at treating cancer, chronic viral infections, and other serious diseases. The company’s lead product candidate, SBT6050, is currently in a Phase I/Ib clinical trial and is designed as a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody, targeting tumors such as breast and non-small cell lung cancers. Silverback is also advancing SBT6290, a preclinical candidate targeting Nectin4 in various cancers, and SBT8230, which aims to treat chronic hepatitis B virus infection. The company employs its proprietary ImmunoTAC technology platform to create therapies that can be systemically administered while acting specifically at disease sites, thereby potentially modulating fundamental disease pathways previously considered inaccessible. Founded in 2016, Silverback Therapeutics is committed to innovative approaches in biopharmaceutical development.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Celgene Corporation is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for cancer and immune-inflammatory diseases. The company aims to provide treatment options for patients with limited alternatives, conducting numerous clinical trials at major medical centers for its investigational compounds. Celgene's research primarily targets incurable hematological cancers, such as multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma, as well as solid tumors like pancreatic cancer and melanoma. Additionally, the company is developing therapies for serious inflammatory conditions, including psoriasis and psoriatic arthritis. With a commitment to improving patient outcomes, Celgene continues to advance its pipeline of biopharmaceutical drugs.

Vedanta Biosciences is a clinical-stage microbiome company focused on developing therapies for immune-mediated and infectious diseases using live bacteria derived from the human microbiome. The company designs orally delivered defined bacterial consortia, leveraging libraries of microbiome-derived strains, proprietary datasets from human interventional studies, and tools for selecting potent strains. Its platform encompasses consortium design and CGMP manufacturing of bacterially defined products, enabling physicians to access live bacteria drugs for autoimmune and inflammatory conditions. Headquartered in Cambridge, Massachusetts, Vedanta Biosciences aims to create a new category of oral therapies arising from defined bacterial communities grown from clonal cell banks.

Galecto is a clinical-stage biotechnology company developing small molecule therapeutics targeting galectin-3 and lysyl oxidase-like 2 for treating severe diseases like fibrosis and cancer. Its lead product candidate, GB0139, is an inhaled inhibitor of galectin-3 for treating severe fibrotic lung diseases such as idiopathic pulmonary fibrosis.

Compugen is a clinical-stage therapeutic discovery and development company based in Israel. It utilizes predictive computational capabilities to identify novel drug targets and biological pathways, focusing on cancer immunotherapy. Its immuno-oncology pipeline includes four clinical-stage programs targeting immune checkpoints.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

The University of North Carolina at Chapel Hill School of Medicine is a professional school within the university that offers degrees in medicine, allied health sciences, and biomedical sciences, including combined programs such as MD/PhD, MD/MPH, and MD/MBA. It aims to improve health and wellbeing by providing leadership and excellence in patient care, education, and research, while fostering a diverse, respectful environment that supports faculty, staff, and learners. The school houses centers focused on health equity and aging and health, including the UNC Center for Health Equity Research, which advances health in underserved communities through research collaborations, and the UNC Center for Aging and Health, which delivers high-quality clinical care to older adults, connects families with resources, and trains the next generation of geriatric professionals.

Enterome develops innovative cancer treatments focusing on generating powerful, long-lasting immune responses using its proprietary OncoMimic technology. The company aims to overcome immune tolerance against cancer cells, with applications across various solid tumors. Its most advanced programs are in Phase 2 clinical trials for hard-to-treat tumors such as glioblastoma, adrenal malignancies, and colorectal cancer.

Cardioxyl Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing innovative therapies for cardiovascular disease. The company is dedicated to discovering, developing, and commercializing novel technologies in areas where existing treatments are lacking or inadequate. With a strong emphasis on nitroxyl technology, Cardioxyl has established significant expertise in its chemistry, biology, and clinical applications. The company's leading candidate, CXL-1020, is currently undergoing clinical development for Acute Decompensated Heart Failure, a condition that is a primary cause of hospitalization among patients over the age of 65. Through its research and development efforts, Cardioxyl aims to address critical unmet needs in cardiovascular care.

Flexus Biosciences, established in 2013 and based in San Carlos, California, is a privately-held biopharmaceutical company dedicated to developing innovative small-molecule cancer therapeutics. Its primary focus lies in targeting regulatory T cells, aiming to create novel immunotherapies that enhance the body's immune response against cancer.

CareDx is a molecular diagnostics company specializing in noninvasive surveillance tests to identify post-transplant injuries and rule out rejection, supporting the entire transplant journey from initial matching to patient care.

Medarex is a biopharmaceutical company dedicated to the discovery, development, and potential commercialization of fully human antibody-based therapeutics aimed at treating life-threatening and debilitating diseases, such as cancer, inflammation, autoimmune disorders, and infectious diseases. The company leverages its UltiMAb technology, along with its expertise in product development and clinical manufacturing, to create and support a diverse range of fully human antibody product candidates. Medarex focuses on advancing these therapeutics for both its own portfolio and in collaboration with partners in the biopharmaceutical industry.

ImClone Systems is a prominent biotechnology company focused on the development and manufacture of therapeutic products aimed at improving oncology care. Established in 1984, the company specializes in creating targeted biologic treatments for various cancers, leveraging advancements in molecular biology, genomics, and antibody engineering. Its flagship product, ERBITUX, is complemented by a diverse pipeline of investigational monoclonal antibodies currently in mid- to late-stage clinical development, targeting major solid tumor types. Following its acquisition by Eli Lilly and Company in 2008, ImClone has enhanced its pipeline development through Lilly's global resources. The company operates state-of-the-art FDA-approved manufacturing facilities in Branchburg, New Jersey, which are among the largest for biologic manufacturing worldwide. Additionally, ImClone has research headquarters in New York City and maintains international operations in Europe, positioning it well to meet the evolving medical needs of cancer patients.

Kosan Biosciences Incorporated, a cancer therapeutics company, focuses on developing various classes of anticancer agents through clinical development. Its product KOS-953, a Hsp90 inhibitor is in Phase III clinical trial in combination with Velcade for multiple myeloma, as well as in Phase II clinical trial in combination with Herceptin for HER2-positive metastatic breast cancer. The company's product portfolio also includes KOS-1584, an epothilone anticancer product candidate evaluated in dose-escalating Phase I clinical trial in patients with solid tumors; KOS-1803, a preclinical stage product for cancer; KOS-2187, a potent motilin receptor agonist that is in Phase I clinical testing for the treatment of GERD. In addition, Kosan Biosciences develops KOS-2464, a preclinical stage product for cancer. The company was founded in 1995 and is based in Hayward, California. As of June 25, 2008, Kosan Biosciences Incorporated operates as a subsidiary of Bristol-Myers Squibb Co.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

GlycoEra is a biotechnology company focused on developing novel therapeutics by harnessing the power of glycan-mediated biology.